At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 561–570 of 620 results.
-
Researchers are assessing the cellular therapy lisocabtagene maraleucel (liso-cel) in people with primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that has not yet been treated. In addition, they cannot have autologous stem cell transplantation (ASCT). During ASCT, a patient's healthy, blood-forming cells are collected before treatment, stored, and returned after treatment with very strong chemotherapy.
-
Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.
-
The purpose of this study is to find the highest dose of the investigational drug RMC-6236 that can be given safely in people with advanced solid tumors containing mutations in the KRAS gene. RMC-6236 targets the KRAS protein made by the mutated gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).
-
Breast cancer (TNBC) and non-small cell lung cancer (NSCLC) that spread to other parts of the body (metastasize) are usually treated with chemotherapy, immunotherapy, targeted therapies, and/or radiation therapy. In this study, researchers want to see if using stereotactic body radiosurgery (SBRT) to all metastatic tumors plus standard therapy is more effective than standard therapy alone in patients with oligometastatic TNBC or NSCLC (five or fewer metastatic tumors).
-
This study will compare the effects of different amounts of aerobic exercise on heart and lung (cardiorespiratory) fitness in post-menopausal women who completed treatment for early-stage breast cancer. Researchers will study the effects of different exercise programs on oxygen use, heart pumping ability, lung function, and blood vessel health. Participants will be randomly assigned to one of four groups:
-
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called "autologous tumor infiltrating lymphocytes" (TIL) therapy. It activates white blood cells to attack the tumor.
-
Researchers want to see if adding zanidatamab to standard treatment works well against biliary tract cancer. The people in this study have biliary tract cancer that has spread or cannot be removed with surgery. In addition, their cancers make a protein called HER2.
-
Researchers want to see how well reparixin works against myelofibrosis. This disease is a rare bone marrow cancer that disrupts your body's normal blood cell production.
-
Researchers want to see how well tivozanib plus pembrolizumab works in people with kidney cancer. The people in this study had surgery for renal cell carcinoma and have a high risk of it coming back.
-
In this study, researchers want to find the highest dose of the drug abemaciclib that can be given safely with ruxolitinib in people with myelofibrosis that has developed on its own (primary myelofibrosis) or as a complication of the blood diseases polycythemia vera or essential thrombocythemia. In people with myelofibrosis, the bone marrow is not able to make enough blood cells. The spleen is bigger than normal, making the stomach feel very full. Patients may also have fever and night sweats.